Loading
Life sciences · Journal article
Scientific Reports · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
B7-H3 is a B7 family immune co-stimulatory molecule that is highly expressed on the surface of many tumors but shows low or undetectable expression in normal tissues, making it a promising target for cancer therapy. To date, several B7-H3-targeted CAR-T therapies based on conventional antibody scFv formats have shown progress in tumor treatment; however, no such products have yet received regulatory approval. Single-domain antibodies (sdAbs), which consist solely of the heavy-chain variable domain, have demonstrated favorable properties across multiple therapeutic modalities. In this study, we screened a fully‑human phage‑display library and identified a B7‑H3‑targeting sdAb, SIPI20006, which exhibited high specificity toward both the 4Ig and 2Ig isoforms of B7‑H3. SIPI20006‑engineered CAR‑T cells exerted antigen‑specific cytotoxicity against B7‑H3‑positive SKOV3 and A172 tumor cells.